Emil D Kakkis - Net Worth and Insider Trading
Emil D Kakkis Net Worth
The estimated net worth of Emil D Kakkis is at least $108 Million dollars as of 2025-04-25. Emil D Kakkis is the President & CEO of Ultragenyx Pharmaceutical Inc and owns about 2,800,716 shares of Ultragenyx Pharmaceutical Inc (RARE) stock worth over $105 Million. Emil D Kakkis is also the Chief Medical Officer of Biomarin Pharmaceutical Inc and owns about 39,621 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $2 Million. Details can be seen in Emil D Kakkis's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Emil D Kakkis has not made any transactions after 2025-02-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Emil D Kakkis
Emil D Kakkis Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Emil D Kakkis owns 2 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , and Biomarin Pharmaceutical Inc (BMRN) .
Click here to see the complete history of Emil D Kakkis’s form 4 insider trades.
Insider Ownership Summary of Emil D Kakkis
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2025-02-28 | director & 10 percent owner & President & CEO |
| BMRN | Biomarin Pharmaceutical Inc | 2009-03-02 | SVP & Business Operations |
Emil D Kakkis Latest Holdings Summary
Emil D Kakkis currently owns a total of 2 stocks. Among these stocks, Emil D Kakkis owns 2,800,716 shares of Ultragenyx Pharmaceutical Inc (RARE) as of February 28, 2025, with a value of $105 Million and a weighting of 97.7%. Emil D Kakkis also owns 39,621 shares of Biomarin Pharmaceutical Inc (BMRN) as of March 2, 2009, with a value of $2 Million and a weighting of 2.3%.
Latest Holdings of Emil D Kakkis
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2025-02-28 | 2,800,716 | 37.64 | 105,418,950 |
| BMRN | Biomarin Pharmaceutical Inc | 2009-03-02 | 39,621 | 62.74 | 2,485,822 |
Holding Weightings of Emil D Kakkis
Emil D Kakkis Form 4 Trading Tracker
According to the SEC Form 4 filings, Emil D Kakkis has made a total of 15 transactions in Ultragenyx Pharmaceutical Inc (RARE) over the past 5 years, including 0 buys and 15 sells. The most-recent trade in Ultragenyx Pharmaceutical Inc is the sale of 98,434 shares on February 28, 2025, which brought Emil D Kakkis around $4 Million.
According to the SEC Form 4 filings, Emil D Kakkis has made a total of 0 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 7,897 shares on March 2, 2009, which brought Emil D Kakkis around $92,395.
Insider Trading History of Emil D Kakkis
- 1
Emil D Kakkis Trading Performance
GuruFocus tracks the stock performance after each of Emil D Kakkis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Emil D Kakkis is -14.31%. GuruFocus also compares Emil D Kakkis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Emil D Kakkis within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Emil D Kakkis's insider trading performs compared to the benchmark.
Performance of Emil D Kakkis
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.47 | | | | | |
| Relative Return to S&P 500(%) | -0.34 | | | | | |
Emil D Kakkis Ownership Network
Ownership Network List of Emil D Kakkis
Ownership Network Relation of Emil D Kakkis
Emil D Kakkis Owned Company Details
What does Ultragenyx Pharmaceutical Inc do?
Who are the key executives at Ultragenyx Pharmaceutical Inc?
Emil D Kakkis is the director & 10 percent owner & President & CEO of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include Chief Financial Officer Howard Horn , CBO & Senior Vice President Thomas Richard Kassberg , and EVP and Chief Medical Officer Eric Crombez .
Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary
Over the past 18 months, Emil D Kakkis made 7 insider transaction in Ultragenyx Pharmaceutical Inc (RARE) with a net sale of 218,434. Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 29,398 shares made by Karah Herdman Parschauer , a net sale of 10,679 shares made by Eric Crombez , and a net sale of 18,548 shares made by Thomas Richard Kassberg .
In summary, during the past 3 months, insiders sold 161,537 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 161,537 shares. During the past 18 months, 340,707 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 340,707 shares.
Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ultragenyx Pharmaceutical Inc Insider Transactions
Emil D Kakkis Mailing Address
Above is the net worth, insider trading, and ownership report for Emil D Kakkis. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Emil D Kakkis's mailing address is: Novato Ca 94949.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
